{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-303796","form_type":"8-K","ticker":"BMEA","cik":"0001840439","company_name":"Biomea Fusion, Inc.","filed_at":"2022-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.632120+00:00","generated_at":"2026-06-21T05:39:38.724104+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Biomea Fusion presents preclinical data for BMF-500 at ASH; IND on track for H1 2023","bullets":["BMF-500 demonstrated picomolar affinity to FLT3 mutations, including ITD and TKD.","Complete tumor regression in FLT3-ITD xenograft models; effect maintained without continuous exposure.","Three-hour pulse of BMF-500 outperformed continuous gilteritinib exposure in cell killing.","IND submission for BMF-500 planned for first half of 2023.","BMF-500 showed high selectivity with minimal off-target cytotoxicity across 20 cancer cell lines."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-303796","json":"https://secwatch.observer/filing/0001193125-22-303796.json","markdown":"https://secwatch.observer/filing/0001193125-22-303796.md","text":"https://secwatch.observer/filing/0001193125-22-303796.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840439/000119312522303796/0001193125-22-303796-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840439/000119312522303796/d424536d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T05:39:38.724104+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}